ClinicalTrials.gg
RecruitingNCT00005095Updated Feb 28, 2025

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

An observational study in Cervical Cancer, Endometrial Cancer and Fallopian Tube Cancer, sponsored by Northwestern University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Northwestern University · Observational

How we know

From the registry’s dates

  • Started Mar 2000; still recruiting 26 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
6,000
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 834 studies in Uterine Cervical Neoplasms with a site in United States — 143 open to participants now, 218 under way, 6 of them phase 3. Uterine Cervical Neoplasms · United States.

Planned enrollment
11th of 124
6,000 · median 138
Started
2000
with 13 others
Observational
126 of 834
20 open now
Primary completion
2030-12
later than 203 of 217 live
Registered
29th of 834
by date

Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, this one is the 11th largest by planned enrollment of the 124 observational ones that give a count, is one of 14 that started in 2000, is one of 126 observational ones, reaches primary completion later than 203 of the 217 other live ones, and was the 29th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

143 of the 834 studies in Uterine Cervical Neoplasms with a site in United States are open now. Recruiting first, the newest first:

138 more — sign in →

All 143 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 80 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 834 studies in Uterine Cervical Neoplasms with a site in United States, or all of them as a file.
02

Study summary

RATIONALE: To improve strategies for detection and prevention of early-stage disease.

PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer among the high risk population and those who have the disease.

Read the detailed description

OBJECTIVES:

  • To identify and develop highly sensitive and specific tumor markers for the detection and management of ovarian cancer and other gynecological malignancies.
  • To identify new prevention approaches and therapies.
  • To identify measures to improve the quality of life for women at increased risk for developing the disease and for women diagnosed with ovarian cancer.

OUTLINE: Subjects undergo periodic specimen and data collection for research studies, including molecular, biochemical, functional, and genetic marker studies. Participants may have samples of blood, tissue, or body fluids (such as ascites, pleural fluid or urine), or any combination of the aforementioned samples obtained to develop tumor markers to detect early stage or recurrent ovarian cancer.

The results from the biomarker research studies will not be reported to the patient or the physician. In the future, if any of the experimental tumor markers are found to be effective in detecting early stage ovarian cancer, and the patient's result is abnormal, the patient and physician will be notified.

Subjects may be asked to complete a combination of questionnaires designed to evaluate psychological functioning among women enrolled in a comprehensive ovarian cancer early detection program who are at increased risk for developing disease as compared to women currently diagnosed with ovarian cancer.

03

Conditions studied

  • Cervical Cancer
  • Endometrial Cancer
  • Fallopian Tube Cancer
  • Hereditary Breast/Ovarian Cancer (brca1, brca2)
  • Ovarian Cancer
  • Sarcoma
  • Uterine Leiomyomata
  • Vaginal Cancer
  • Vulvar Cancer

Keywords

  • ovarian epithelial cancer
  • hereditary breast/ovarian cancer (BRCA1, BRCA2)
  • fallopian tube cancer
  • ovarian germ cell tumor
  • ovarian sarcoma
  • ovarian stromal cancer
  • endometrial cancer
  • uterine sarcoma
  • vaginal cancer
  • cervical cancer
  • vulvar cancer
  • uterine leiomyomata
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Women at high risk of ovarian cancer due to family or personal medical history, or a gynecologic abnormality.

Eligibility criteria

DISEASE CHARACTERISTICS:

  • Meets one of the following criteria:

    • Considered to be at increased risk for developing ovarian cancer, as defined by one of the following:

      • Has at least one first-degree relative (mother, sister, or daughter) with ovarian, primary peritoneal, or fallopian tube cancer
      • Has at least two first or second degree relatives diagnosed before age 50 with either ovarian, primary peritoneal, fallopian tube, and/or pancreatic cancer who have tested positive for hereditary cancer syndrome that includes an increased risk of gynecologic cancer (e.g., BRCA1/2 or Lynch Syndrome)or have increased risk as deemed by a certified genetic counselor
      • A personal or family history of a hereditary cancer syndrome that includes an increased risk of gynecologic cancer
      • Increased risk as deemed by a certified genetic counselor
    • Undergoing surgery for a gynecologic condition, including any of the following:

      • Diagnosis of a reproductive cancer
      • Benign gynecological condition (e.g., uterine leiomyomata, endometriosis, pelvic inflammatory disease, or follicular or corpus luteum ovarian cysts)
      • Highly suspicious adnexal mass
      • Risk-reducing prophylactic oophorectomy

PATIENT CHARACTERISTICS:

Age

  • Between the ages of 18 and 80
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
6,000 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • High Risk for Ovarian Cancer

    Women who are at increased risk of ovarian cancer based on family or personal medical history who are participating in the Northwestern Ovarian Cancer Early Detection and Prevention Program clinic.

    Other: Ca-125 · Other: screening questionnaire administration · Procedure: Surgery

  • Suspected or diagnosed gynecological condition

    Women who are planning to undergo surgery for their gynecological condition

  • Control Group

    Healthy subjects with no history of cancer and at general risk.

Interventions

  • OtherCa-125

    Subject's blood collected at their follow-up blood draw will be assessed for biomarkers that could lead to a panel for detecting early stage ovarian cancer.

  • Otherscreening questionnaire administration

    Questionnaires designed to assess quality of life for women at increased risk of ovarian cancer will be administered to the subjects. Clinical data will also be collected.

    Also known as: Questionnaire

  • ProcedureSurgery

    Subjects will be assessed for high risk factors.

    Also known as: BSO, fallopian tubes, TAH, hysterectomy, bilateral salpingectomy, STIC

06

What researchers measure

Primary outcomes

  1. The development of ultrasound and serum tumor markers for the detection and management of ovarian cancer and other

    To identify markers to allow for presymptomatic testing for ovarian and other gynecological malignancies

    Time frame: 1 year

Secondary outcomes

  1. new prevention approaches and therapies for risk assessment

    To identify new prevention approaches and therapies by researching and reviewing the risk of developing disease.

    Time frame: 1 year

  2. The develop of measures to improve the quality of life for women at increased risk for developing the disease and for women diagnosed with ovarian cancer

    To identify the measurements to improve the quality of life for women at increased risk for developing the disease

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University
    Chicago, Illinois 60611-3013, United States
    Recruiting
    • Clinical Trials Office - Robert H. Lurie Comprehensive Cancer · Contactcancer@northwestern.edu · 312-695-1301
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2000 (actual). Primary completion is estimated for Dec 2030, 369 months after the start.

Of 190 non-industry observational studies under Uterine Cervical Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 158. This study's planned 369 months is above that.

Counting every sponsor, half of 214 studies reached it within 58 months; a quarter within 28 and three quarters within 158.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2000
First posted
Jan 27, 2003
StartActual
Mar 2000
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2040
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00005095
Responsible party
Lee Shulman (Professor, Northwestern University) — Principal investigator
First posted
Jan 27, 2003
Start date
Mar 2000
Primary completion
Dec 2030 (estimated)
Completion
Dec 2040 (estimated)
Last update
Feb 28, 2025

Study contacts

Takelia Walker
Contact
takelia-watson@northwestern.edu
3125034802
Anne Grace
Contact
anne@northwestern.edu
312-503-4165
Lee P. Shulman, MD
study chair · Robert H. Lurie Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion